QR Kod

Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023 [version 2; peer review: 1 approved, 2 approved with reservations]

Background It is increasingly suggested that clinical guidelines and practices be updated to permanently expand relaxation around access to opioid agonist treatment (OAT) take-home doses after COVID-19. Despite a risk of OAT drug diversion, flexibility in take-home doses is valued by patients and as...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Suzi Lyons, Kathleen Bennett, Gráinne Cousins, Louise Durand, Andy O'Hara, Des Crowley, Eamon Keenan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: F1000 Research Ltd 2025-04-01
Seri Bilgileri:HRB Open Research
Konular:
Opioid Agonist Treatment
Take-home dosing
Opioid Use Disorder
Covid-19
retention
mortality
eng
Online Erişim:https://hrbopenresearch.org/articles/8-32/v2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller